These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7533681)

  • 1. The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response--an in vivo model of Th2-like activity.
    Bundick RV; Craggs RI; Holness E
    Clin Exp Immunol; 1995 Mar; 99(3):467-72. PubMed ID: 7533681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
    Bierer BE
    Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for new hair growth.
    Iwabuchi T; Maruyama T; Sei Y; Adachi K
    J Dermatol Sci; 1995 Jan; 9(1):64-9. PubMed ID: 7537082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modes of action of FK506, cyclosporin A, and rapamycin.
    Morris R
    Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
    [No Abstract]   [Full Text] [Related]  

  • 5. Divergent effects of rapamycin on mouse and rat cells following mitogenic stimulation.
    Olivera DL; Kaplan JM; Newman-Tarr T; Ruggieri EV; Badger AM
    Clin Immunol Immunopathol; 1993 Sep; 68(3):357-62. PubMed ID: 7690317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin).
    High KP; Washburn RG
    J Infect Dis; 1997 Jan; 175(1):222-5. PubMed ID: 8985226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture.
    Wera S; Zheng L; Hooghe-Peters EL; Belayew A; Martial JA; Velkeniers B
    Endocr Res; 1995 Aug; 21(3):623-33. PubMed ID: 7588431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of in vitro and in vivo immunosuppressive potential of cyclosporin G with cyclosporin A and FK-506.
    Saada V; Pham-Huy C; Voisin J; Righenzi S; Rucay P; Claude JR; Duc HT
    Int J Immunopharmacol; 1996 Jan; 18(1):79-87. PubMed ID: 8732436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists.
    Hatfield SM; Mynderse JS; Roehm NW
    J Pharmacol Exp Ther; 1992 Jun; 261(3):970-6. PubMed ID: 1376361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporin A, FK506, rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions.
    Kahan BD
    J Am Soc Nephrol; 1992 Jun; 2(12 Suppl):S222-7. PubMed ID: 1379841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin.
    Wicker LS; Boltz RC; Matt V; Nichols EA; Peterson LB; Sigal NH
    Eur J Immunol; 1990 Oct; 20(10):2277-83. PubMed ID: 1700753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells.
    Ogawa T; Tokuda M; Tomizawa K; Matsui H; Itano T; Konishi R; Nagahata S; Hatase O
    Biochem Biophys Res Commun; 1998 Aug; 249(1):226-30. PubMed ID: 9705862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia.
    Sharkey J; Butcher SP
    Nature; 1994 Sep; 371(6495):336-9. PubMed ID: 7522303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of cyclosporin A, FK506 and rapamycin on the murine contact sensitivity reaction.
    Salerno A; Bonanno CT; Caccamo N; Cigna D; Dominici R; Ferro C; Sireci G; Dieli F
    Clin Exp Immunol; 1998 Apr; 112(1):112-9. PubMed ID: 9566798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation.
    Mollison KW; Fey TA; Krause RA; Thomas VA; Mehta AP; Luly JR
    Ann N Y Acad Sci; 1993 Jun; 685():55-7. PubMed ID: 7689812
    [No Abstract]   [Full Text] [Related]  

  • 16. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
    Hess DA; Bird IA; Almawi WY; Rieder MJ
    J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin.
    Duncan JI
    J Invest Dermatol; 1994 Jan; 102(1):84-8. PubMed ID: 7507155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin].
    Rondeau E
    Nephrologie; 1992; 13(3):137. PubMed ID: 1379348
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of cyclosporin A, rapamycin, and FK520 on peripheral T-cell deletion and anergy.
    Prud'homme GJ; Vanier LE; Bocarro DC; Ste-Croix H
    Cell Immunol; 1995 Aug; 164(1):47-56. PubMed ID: 7543371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cyclosporin A, FK506 and rapamycin on proliferation and soluble IL-2 receptor release from mitogenically stimulated rat spleen cells.
    Pockley AG; Williams S; Reid SD; Bowles MJ
    Biochem Soc Trans; 1995 Nov; 23(4):615S. PubMed ID: 8654800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.